Maurizio Fanciulli
Overview
Explore the profile of Maurizio Fanciulli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
2688
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bruno T, Catena V, Blandino G, Fanciulli M, Di Agostino S
J Exp Clin Cancer Res
. 2024 Dec;
43(1):322.
PMID: 39695699
Multiple myeloma (MM), a hematologic malignancy characterized by the clonal expansion of plasma cells within the bone marrow, is associated with severe health complications, including osteolytic bone lesions that significantly...
2.
Musella M, Guarracino A, Manduca N, Galassi C, Ruggiero E, Potenza A, et al.
Nat Immunol
. 2024 Sep;
25(11):2166.
PMID: 39289560
No abstract available.
3.
Travaglini S, Silvestrini G, Attardi E, Fanciulli M, Scalera S, Antonelli S, et al.
Leuk Res
. 2024 Aug;
145:107568.
PMID: 39180902
Acute myeloid leukemia (AML) with inv(16) is typically associated with a favourable prognosis. However, up to 40 % of patients will eventually experience disease relapse. Herein, we dissected the genomic...
4.
Scalera S, Ricciuti B, Marinelli D, Mazzotta M, Cipriani L, Bon G, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4397-4411.
PMID: 38980931
Purpose: Co-occurring mutations in KEAP1 and STK11/KRAS have emerged as determinants of survival outcomes in patients with non-small cell lung cancer (NSCLC) treated with immunotherapy. However, these mutational contexts identify...
5.
Corleone G, Sorino C, Caforio M, Di Giovenale S, De Nicola F, Goeman F, et al.
J Exp Clin Cancer Res
. 2024 Jun;
43(1):179.
PMID: 38926853
Background: Enhancer reprogramming plays a significant role in the heterogeneity of cancer. However, we have limited knowledge about the impact of chromatin remodeling in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)...
6.
Iaiza A, Mazzanti G, Goeman F, Cesaro B, Cortile C, Corleone G, et al.
Cell Mol Life Sci
. 2024 Jun;
81(1):276.
PMID: 38909325
N-methyladenosine (mA) is one of the most prevalent and conserved RNA modifications. It controls several biological processes, including the biogenesis and function of circular RNAs (circRNAs), which are a class...
7.
Ascenzi F, Esposito A, Bruschini S, Salvati V, De Vitis C, De Arcangelis V, et al.
Cell Death Dis
. 2024 Apr;
15(4):303.
PMID: 38684666
Scientific literature supports the evidence that cancer stem cells (CSCs) retain inside low reactive oxygen species (ROS) levels and are, therefore, less susceptible to cell death, including ferroptosis, a type...
8.
Pulito C, Mori F, Sacconi A, Goeman F, Ferraiuolo M, Pasanisi P, et al.
Cell Discov
. 2024 Mar;
10(1):29.
PMID: 38480687
No abstract available.
9.
Bruno T, Catena V, Corleone G, Cortile C, Cappelletto M, Bellei B, et al.
Leukemia
. 2024 Feb;
38(4):877-882.
PMID: 38368441
No abstract available.
10.
Giacomini P, Valenti F, Allegretti M, Pallocca M, De Nicola F, Ciuffreda L, et al.
J Transl Med
. 2023 Oct;
21(1):725.
PMID: 37845764
Background: Molecular Tumor Boards (MTB) operating in real-world have generated limited consensus on good practices for accrual, actionable alteration mapping, and outcome metrics. These topics are addressed herein in 124...